A pilot study of rituximab in combination with out-patient based VGF [vinorelbine + gemcitabine + pegfilgrastim]/F-GIV [gemcitabine + ifosfamide + vinorelbine + pegfilgrastim] salvage therapies for relapsed/refractory CD20+ lymphomas
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Gemcitabine; Ifosfamide; Rituximab; Vinorelbine
- Indications Non-Hodgkin's lymphoma
- Focus Adverse reactions
- 15 Jan 2016 Biomarkers information updated
- 23 Oct 2007 Status changed from recruiting to completed.
- 04 Feb 2006 New trial record.